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Abstract Intravesical bacillus Calmette-Guerin (BCG)
therapy is considered the most successful immunotherapy
against solid tumors of human bladder carcinoma. To deter-
mine the actual eVector cells activated by intravesical BCG
therapy to inhibit the growth of bladder carcinoma, T24
human bladder tumor cells, expressing very low levels of
class I MHC, were co-cultured with allogeneic peripheral
blood mononuclear cells (PBMCs) with live BCG. The pro-
liferation of T24 cells was markedly inhibited when BCG-
infected dendritic cells (DCs) were added to the culture
although the addition of either BCG or uninfected DCs
alone did not result in any inhibition. The inhibitory eVect
was much stronger when the DCs were infected with live
BCG rather than with heat-inactivated BCG. The live
BCG-infected DCs secreted TNF- and IL-12 within a day
and this secretion continued for at least a week, while the
heat-inactivated BCG-infected DCs secreted no IL-12 and
little TNF-. Such secretion of cytokines may activate
innate alert cells, and indeed NKT cells expressing IL-12
receptors apparently proliferated and were activated to pro-
duce cytocidal perforin among the PBMCs when live BCG-
infected DCs were externally added. Moreover, depletion
of  T-cells from PBMCs signiWcantly reduced the cyto-
toxic eVect on T24 cells, while depletion of CD8 cells did
not aVect T24 cell growth. Furthermore, the innate eVectors
seem to recognize MICA/MICB molecules on T24 via
NKG2D receptors. These Wndings suggest the involvement
of innate alert cells activated by the live BCG-infected DCs
to inhibit the growth of bladder carcinoma and provide a
possible mechanism of intravesical BCG therapy.
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Introduction
Intravesical bacillus Calmette-Guerin (BCG) therapy is
considered the most successful immunotherapy against
solid tumors in cases of human superWcial bladder carci-
noma particularly in preventing from its recurrence [1, 4].
Intravesical immunotherapy with live BCG results in a
massive local immune response characterized by the secre-
tion of various cytokines in the urine [14, 27] or bladder
tissue as well as by the inWltration of granulocytes and
mononuclear cells into the bladder wall after repeated treat-
ment with BCG instillation [3, 21], indicating the immuno-
pathological responses induced at the local mucosal
compartment may correlate with the BCG-mediated anti-
tumor eVect. However, neither the precise mechanisms nor
the actual eVector cells underlying the anti-tumor eVect that
BCG therapy stimulates remain to be elucidated.
The bladder is a conWned mucosal compartment, where
BCG is able to be maintained at a high concentration and
thus may achieve long-lasting, continuous immune activa-
tion, which seems to better stimulate innate local immunity
having broad cross-reactivity with less memory rather than
acquired systemic immunity with high speciWcity and
memory originated from rearranged genes. Therefore, live
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eVectors such as T lymphocytes [17, 18] and CD1 mole-
cule-restricted lipid/glycolipid antigen-speciWc T cells
including CD1d-restricted natural killer T (NKT) cells [12,
13] via live BCG-infected dendritic cells (DCs). Such DCs
express not only peptide antigen-loaded individually
restricted class I and II MHC molecules but also species-
speciWc CD1 molecules on their surface to present BCG-
derived lipid/glycolipid antigens [15, 20]. Indeed, Wndings
that live BCG-infected DCs can be recognized by CD1
molecule-restricted but not by class I MHC molecule-
restricted CD8+ T cells [16] and that the V2V2 T lym-
phocytes response to BCG by immunization in macaques
with live BCG [5] have recently been reported. Moreover, a
close relationship between BCG-immunization, and NKT
cell activation has also been shown [9]. Therefore, continu-
ous stimulation in the conWned bladder space with live
BCG may activate those local innate eVectors, which may
control bladder cancer expansion in vivo.
The cell line T24, a well-known cell for human bladder
cancer [19], expresses markedly down-modulated MHC
class I molecules on the cell surface in comparison with
normal peripheral blood mononuclear cells (PBMCs).
Hence, the T24 line is possibly regulated by cells in a class
I MHC molecule-unrelated manner rather than by the autol-
ogous class I MHC molecule-restricted conventional CD8-
positive cytotoxic T lymphocytes (CTLs). Therefore, we
co-cultured T24 cells with allogeneic PBMCs pretreated
with live BCG to determine the actual cells activated by the
BCG for controlling T24 tumor cell proliferation and elimi-
nation, and found that innate alert cells such as V2V2 T
cells and particularly NKT cells derived from allogeneic
PBMCs activated by the live BCG-pretreated DCs appear
to inhibit the proliferation of T24 tumor cells as well as
eliminate them. The Wndings shown in the present study
strongly suggest the involvement of innate alert eVectors in
controlling bladder cancer growth and shed light on the




Human urinary bladder carcinoma T24 cells (ATCC HTB-
4) were cultured in McCoy’s 5a medium (Invitrogen,
Carlsbad, CA) supplemented with 10% FCS (HyClone
Laboratories, Logan, UT), 50 U/ml penicillin (Invitrogen),
and 50 mg/ml streptomycin (Invitrogen). Human colon
cancer derived HCT116 cells (ATCC CCL 247), C1R cells
were cultured in Dulbecco’s modiWed Eagle’s medium
(Sigma-Aldrich, St Louis, MO) supplemented with 10%
FCS (HyClone), 50 U/ml penicillin, and 50 mg/ml strepto-
mycin (Invitrogen). Myelogenous leukemia K562 cells, and
T lymphoblast Jurkat cells were cultured in RPMI 1640
(Sigma-Aldrich, St Louis, MO)-based complete T-cell
medium (CTM) [25] supplemented with 10% FCS, 2 mM
L-glutamine (ICN Biomedicals, Aurora, OH), 100 units/ml
penicillin, 100 g/ml streptomycin, 1 mM HEPES (Invitro-
gen), 1 mM sodium pyruvate (Invitrogen), 50 mM
2-mercaptoethanol (2-ME) (Invitrogen).
Infection of DCs with live or heat-inactivated BCG
A lyophilized preparation of BCG, the Tokyo 172 strain
(12 mg dry weight per ample) (Japan BCG Laboratory,
Tokyo, Japan) was used to carry out the experiments. For
the infection experiments, BCG was harvested at a mid-log
growth phase, washed, and suspended in RPMI 1640
medium supplemented with 10% FCS. The suspension was
passed through a 5-m pore size Wlter to obtain single-cell
bacteria. The viability of bacteria was constantly >90%.
The BCG preparation was divided into two equal aliquots;
one incubated for 30 min at 85°C to kill the bacteria and the
other left at room temperature as reported recently [16].
Generation of DCs from PBMCs and their treatment 
with BCG
DCs were obtained from PBMCs as described recently
[26]. In brief, PBMCs were freshly isolated with
Ficoll-Hypaque (Amersham-Pharmacia Biotech, Uppsala,
Sweden) from peripheral blood of healthy volunteers, and
CD14+ monocytes were immediately separated by mag-
netic depletion using a monocyte isolation kit (Miltenyi
Biotec, Bergisch Gladbach, Germany) containing hapten-
conjugated antibodies to CD3, CD7, CD19, CD45RA,
CD56, and anti-IgE Abs and a magnetic cell separator
(MACS, Miltenyi Biotec) according to the manufacturer’s
instructions, routinely resulting in >90% purity of CD14+
cells. Cells were cultured in 24-well plates for 6–7 days in
CTM supplemented with 200 ng/ml GM-CSF (PeproTech,
Rocky Hill, NJ), and 10 ng/ml IL-4 (Biosource Intl.,
Camarillo, CA) to obtain DCs. For the treatment with BCG,
1 £ 105 DCs in 1 ml of CTM were incubated overnight
with 0.1 mg of either live BCG or heat-inactivated BCG.
After being washed three times with RPMI1640 medium,
the BCG-treated DCs were further co-cultured with 1 £ 106
PBMCs of the same donor to carry out the experiments.
Antibodies and Xow-cytometric analysis
Fluorescein isothiocyanate (FITC)-conjugated anti-human
monoclonal antibodies (mAbs) to mouse IgG1, isotype
control (MOP-21), HLA-ABC (G46-2.6), CD3 (H1T3a),123
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[2331(FUN-1)], as well as phycoerythrin (PE)-conjugated
mouse IgG1, isotype control, CD3, CD56 (B159), and
unlabeled anti-human CD3, CD4 (RPA-T4), V2 (B6), and
CD161, were all purchased from BD Biosciences (San
Diego, CA). Unlabeled anti-human CD8 (2ST8.5H7)
mAb was purchased from IMMUNOTECH (Marseille,
Cedex, France). Cells were stained with the relevant anti-
body on ice for 30 min in phosphate-buVered saline (PBS)
with 2% FCS and 0.01 M sodium azide (PBS-based
medium), washed twice, and re-suspended in the PBS-
based medium. Then, the labeled cells were analyzed with a
FACScan (BD Biosciences) using CellQuest software (BD
Biosciences). Live cells were gated based on propidium
iodide gating.
Depletion of cells from PBMCs
To deplete V2-positive cells, PBMCs were incubated with
mouse anti-human V2 mAb (B6) for 30 min at 4°C
and washed three times to remove free mAb. Then the
stained cells were further incubated with magnetic beads-
conjugated anti-mouse IgG (Dynabeads Pan Mouse IgG)
(DYNAL BIOTECH, Oslo, Norway), and V2-positive
cells were eliminated by magnetic device (Perspective Bio-
systems, Framingham, MA) following the manufacturer’s
instruction. CD8, CD3, CD161, and CD4-positive cells
were also depleted using the same procedure.
QuantiWcation of cytokine production from BCG-treated 
DCs by ELISA
Monocyte-derived DCs (1 £ 106) were incubated with 1 ml
of CTM containing 0.1 mg of BCG in 24-well culture plate
for 2–3 days and the culture supernatants were collected
and stored at ¡80°C until the measurement of cytokines.
Production of TNF-, IL-12, IL-10, and IL-4 was measured
using the DuoSet ELISA Development Kit (R&D systems,
Minneapolis, MN) according to the manufacturer’s instruc-
tions.
Chromium-51 release assay
The cytotoxicity of BCG-activated cells was measured by a
standard 4-h 51Cr-release assay using T-24 human bladder
cancer cells or NK-sensitive K562 myelogenous leukemia
cells as targets. In brief, various numbers of eVector cells
were incubated with 3 £ 103 51Cr-labeled targets for 4 h at
37°C in 200 l of RPMI 1640 medium containing 10%
FCS in round-bottomed 96-well cell culture plates (BD
Biosciences). After incubation, the plates were centrifuged
for 10 min at 330£g, and 100 l of cell-free supernatant
was collected to measure radioactivity with a Packard Auto-
Gamma 5650 counter (Hewlett-Packard Japan, Tokyo, Japan).
Maximum release was determined from the supernatant of
cells that had been lysed by the addition of 5% Triton £-100
and spontaneous release was determined from target cells
incubated without added eVector cells. The percent speciWc
lysis was calculated as 100£ (experimental release –
spontaneous release)/(maximum release – spontaneous
release). Standard errors of the means of triplicate cultures
were always <5% of the mean. Data are expressed as the
mean § SEM. Each experiment was performed at least
three times.
T24 growth inhibition assay
The T24 growth inhibition assay was performed by incu-
bating 1 £ 104 T24 cells with 5 £ 104 or 1 £ 105 freshly
isolated allogeneic PBMCs in 200 l of CTM for 3 days at
37°C in 5% CO2 based on a recent study [22]. Samples
were cultured in triplicate on 96-well U-bottom plates. The
cells were then labeled for 16 h with 1 Ci/well of tritiated
thymidine (3H-TdR; MP Biomedicals, Morgan, CA), har-
vested in an automated plate harvester (TomTech, Orange,
CT), and counted in a 1,450 Micro Beta TRILUX scintilla-
tion spectrometer (Wallac, Gaithersburg, MD). Data are
expressed as the mean count per minute (cpm) § SEM.
RT-PCR for CD1d mRNA in T24 cells
Total RNA was extracted from T24, Jurkat, and HCT cells
using the RNeasy Protocol Mini Kit (Qiagen, Valencia,
CA) according to the manufacturer’s instructions. RNA
(2 g) was reverse transcribed with oligo-(dT)18 (Perkin
Elmer, Wellesley) priming and Superscript III (Invitrogen)
reverse transcriptase in a 20 g reaction mixture at 50°C for
60 min. A measure of 1 l (equal to about 200 ng) of the
cDNA product was then subjected to 30 cycles of 30 s at
94°C, 1 min at 64°C, and 1 min Wnal extension at 72°C,
with a thermocycler (PCR express; Hybaid, Teddington,
Middlesex, UK). The ampliWcation was performed in a
reaction volume of 20 l with LA PCR buVer (Takara,
Shiga, Japan), composed of 2.5 mM MgCl2, 0.3 nM of each
deoxynucleotide triphosphate, 2.5 mM of each primer, and
1 U of LA Taq polymerase (Takara). The following oligo-
nucleotide primers were designed from the published
cDNA sequence [6]: GAPDH sense-primer (5-GCCTCAA
GATCATCAGCAATGC-3) and antisense-primer (5-AT
GCCAGTGAGCTTCCCGTTC-3), human CD1d (hCD1d)
full-length sense-primer (5-CGGGATCCATGGGGTGC
CTGCTGTTTCTG-3), antisense-primer (5-ATTTGCGG
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eVctors through NKG2D-receptor against MICA/MICB 
molecules on T24 tumor cells
Cytotoxicity of innate eVectors activated by live BCG-
treated DC against T24 cells was investigated using
51-chromium release assay shown above in the presence of
various blocking antibodies such as anti-human MICA/
MICB (6D4) (BioLegend, San Diego, CA), anti-human
NKG2D (CD314)-speciWc mouse mAbs (1D11) (BioLeg-
end), or isotype-matched control mouse IgG1 (BD Bio-
sciences). CD3+CD56+ NKT cells were sorted out with
FACS-Vantage SE (BD Biosciences) according to the
manufacturer’s instruction.
Results
T24 growth inhibition by allogeneic PBMCs activated 
with live BCG-treated DCs
The bladder cancer cell line T24, a well-known cell for
human bladder cancer, expresses markedly reduced levels
of MHC class I molecules on the cell surface in comparison
with normal PBMCs (data not shown). Thus, the T24 line is
possibly regulated by cells in a class I MHC molecule-unre-
lated manner rather than by the autologous class I MHC
molecule-restricted conventional CTLs. Therefore, we used
allogeneic PBMCs to gain insight into the actual cells acti-
vated by BCG for controlling T24 tumor cell proliferation
and elimination.
When 5 £ 104 or 1 £ 105 freshly isolated allogeneic
PBMCs were co-cultured with 1 £ 104 T24 cells in the
presence of live BCG, strong inhibition of T24 cell prolifer-
ation measured with 3H-TdR was observed as compared
with BCG-absent control (Fig. 1a). Because the BCG-sus-
ceptible cells are thought to be DCs, DCs from the PBMCs
were pretreated with (0.1 mg/ml) live BCG for 6 h at 37°C.
Then, after conWrmation that the addition of live BCG-pre-
treated DCs alone did not aVect the T24 cell proliferation,
1 £ 104 T24 cells were incubated with an equal number of
the indicated DCs together with 5 £ 104 or 1 £ 105 alloge-
neic PBMCs of the same donor. Profound inhibition of T24
cell proliferation was observed when live BCG-infected
DCs were co-cultured with PBMCs of the same donor
(Fig. 1b). Moreover, the eVect of live or heat-inactivated
BCG-treated DCs on T24 cell proliferation was also exam-
ined. As indicated in Fig. 1c, the addition of heat-inacti-
vated BCG-pretreated DCs resulted in partial inhibition of
the proliferation. These results indicated that some cells
derived from allogeneic PBMCs activated by the live BCG-
pretreated DCs might gain the capacity to inhibit the prolif-
eration of T24 tumor cells.
Fig. 1 Inhibition of T24 growth by allogeneic PBMCs activated with
live BCG-treated DCs. a When 5 £ 104 or 1 £ 105 freshly isolated allo-
geneic PBMCs were co-cultured with 1 £ 104 T24 cells in the presence
of live BCG (closed triangle), strong inhibition of T24 cell proliferation
measured by 3H-TdR was observed in comparison with the BCG-absent
control (closed circle). b T24 cells (1 £ 104) were incubated with
5 £ 104 or 1 £ 105 allogeneic PBMCs. Profound inhibition of T24 cell
proliferation was observed when live BCG-infected DCs were co-
cultured with PBMCs (closed square). However, no inhibition was
observed when T24 cells were co-cultured either with PBMC alone
(closed circle) or with PBMC plus BCG-uninfected DCs (closed trian-
gle). c T24 cells (1 £ 104) were incubated with 5 £ 104 or 1 £ 105
allogeneic PBMCs plus live BCG-treated DCs (closed triangle),
heat-inactivated BCG-treated DCs (closed square), or control untreated
DCs (closed circle). Again, strong inhibition of T24 cell proliferation
was observed when PBMCs were co-cultured with live BCG-infected
DCs (closed triangle) and partial inhibition was seen when they were
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Next, the live BCG-treated DCs were compared with the
inactivated BCG-treated DCs in terms of the kinetics of
cytokine secretion. As demonstrated in Fig. 2a with closed
columns, live BCG-treated DCs secreted quite a large
amount of IL-12 2–3 days after the incubation, however,
heat-inactivated BCG-treated DCs shown with open col-
umns secreted almost no detectable amount of IL-12. As
for TNF-, live BCG-treated DCs secreted more of it than
heat-inactivated BCG-treated DCs (Fig. 2b). In contrast,
the amount of IL-10 secretion was almost the same between
the two (Fig. 2c). Furthermore, the expression levels of co-
stimulated molecules, CD80 and CD86, were higher in live
BCG-treated DCs (data not shown).
T24 growth inhibition was mainly mediated through 
CD8-negative T cells
These Wndings suggest live BCG-activated DCs to activate
eVectors from PBMCs to inhibit T24 cell proliferation
through the secretion of IL-12 and TNF-. Therefore, to
examine the actual cells that eliminate T24, CD3-positive T
cells were eliminated from among the activated PBMCs
with live BCG-treated DCs, and the cytotoxicity against
51Cr-labeled T24 targets was measured. The cytotoxicity
was signiWcantly reduced by the elimination of the CD3-
positive cells (Fig. 3a). The remaining weak cytotoxicity,
shown as open circles in Fig. 3a, might be due to the eVect
of activated non-T cells such as NK cells. Moreover, the
cytotoxicity against T24 cells was not inhibited by the elim-
ination of CD8-positive cells (shown as closed squares)
(Fig. 3b). These results suggest that the class I MHC mole-
cule-restricted conventional CD8-positive CTL do not
seem to be involved in this T24-related cytotoxicity.
T24 tumor growth was partially inhibited by V2V2 T 
cells
Collectively, the cytotoxity against T24 cells mediated
through live BCG-treated DCs appeared to be provided by
the major eVectors of innate immunity; NK cells, NKT
cells, and  T cells. Thus, we then examined the possible
involvement of T cell eVectors in the elimination of
tumor cells.  T cells are classiWed into two distinct types,
type-1 expressing V1V1 T-cell receptor (TCR) and type-
2 expressing V2V2 TCR, with the majority of cells gen-
erated by BCG reported to be the latter type-2  T cells
[11]. When the V2-positive type-2 T cells were elimi-
nated from live BCG-activated PBMCs, slight inhibition of
the cytotoxicity against T24 cells was observed and this
was apparent when the V2-positive cells were depleted
from PBMCs before co-culturing with BCG-treated DCs
(Fig. 3c). Moreover, PBMCs treated with risedronate, an
activator of V2 [8], showed strong anti-tumor eVect
against T24 cells (Fig. 3d). These results indicate the
involvement of live BCG-activated V2V2 TCR-express-
ing type-2 T cells in the elimination of T24 tumor cells.
Fig. 2 Measurement of cytokine production by BCG-treated DCs.The
diVerence in the kinetics of cytokine secretion between live BCG-treat-
ed DCs and inactivated BCG-treated DCs was compared. Live BCG-
treated DCs (closed column) secreted predominantly large amounts of
IL-12 (a) and larger amounts of TNF- (b) than heat-inactivated BCG-
treated DCs (open column), while the amount of IL-10 secretion (c)









































1250 Cancer Immunol Immunother (2009) 58:1245–1255EVect of depletion of CD161-positive cells on T24 growth
CD161 is known as a marker for NK and NKT cells. Thus,
to examine the eVect of NK and NKT cells on the elimina-
tion of T24 cells, CD161-positive cells were depleted from
PBMCs activated by live BCG-treated DCs, and their elim-
ination was conWrmed by Xowcytometry (Fig. 4a). After
conWrming that the CD161-positive cells were depleted, the
cytotoxicity of the remaining cells against T24 cell was
measured by 51Cr-release assay. A profound reduction in
the cytotoxity was observed when the CD161-positive cells
were eliminated and the reduced cytotoxicity was slightly
greater than that of the activated PBMCs co-cultured with
live BCG-treated DCs (Fig. 4b). These Wndings suggest the
residual T cells after the elimination of CD161-positive
cells to be slightly more cytotoxic than the activated NK
cells in PBMCs. Also, as shown in Fig. 4c, that the live
BCG-activated PBMCs showed far stronger cytotoxicity
than untreated PBMCs against K562 cells that are known to
be sensitive to NK cells indicates NK cells to be less cyto-
toxic to T24 tumor cells than innate T or NKT cells.
Taken together, these results suggest the most potent eVec-
tors among the live BCG-activated cells against T24 seem
to be NKT cells.
SigniWcant production and increase of perforin in the NKT 
cell population among PBMCs co-cultured with live 
BCG-treated DCs
Thus, to conWrm the actual number and increase of NKT
cells among PBMCs co-cultured with live BCG-treated
DCs, a Xow-cytometric analysis was performed. The results
showed that the number of both CD3+CD56+ cells and
CD3+CD161+ NKT cells but not CD3¡CD56+ or
CD3¡CD161+ NK cells apparently increased among those
PBMCs activated by live BCG-treated DCs but not by heat-
Fig. 3 T24 growth inhibition was partially mediated through CD8-
negative V2V2 T cells. a When CD3-positive T cells were elimi-
nated from among the activated PBMCs with live BCG-treated DCs,
the cytotoxicity against T24 tumor cells was signiWcantly reduced
(open circle) almost to the basal level mediated by normal PBMC
(closed circle) or PBMC plus untreated DCs (closed square) in com-
parison with positive PBMCs activated with live BCG-treated DCs
(closed triangle) and the remaining weak cytotoxicity might be due to
the eVect of activated non-T cells such as NK cells. b Such cytotoxicity
against T24 cells was not abrogated by the elimination of CD8-posi-
tive cells (closed square). The results suggest the class I MHC mole-
cule-restricted conventional CD8-positive CTLs do not seem to be
involved in this T24-related cytotoxicity. The elimination of CD4-
positive cells (open circle) from live BCG-activated PBMCs (closed
triangle) did not result in any reduction of cytotoxicity against T24 tar-
gets in comparison with the basal level mediated by normal PBMC
plus untreated DCs (closed circle). c When the V2-positive cells were
depleted from PBMCs before co-culturing with live BCG-treated DCs
(closed square), the cytotoxicity against T24 was apparently reduced
nearly by half in comparison with PBMCs activated with live BCG-
treated DCs (closed triangle). d Moreover, the V2 cell-enriched pop-
ulation from PBMCs co-cultured with risedronate showed a strong
anti-tumor eVect against T24 cells (closed circle). The elimination of
type-2 T cells resulted in a signiWcant reduction in the cytotoxicity
against T24 cells (closed triangle). These results indicate the involve-
ment of live BCG-activated V2V2 TCR-expressing type-2 T cells
in the elimination of T24 tumor cells
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Cancer Immunol Immunother (2009) 58:1245–1255 1251inactivated BCG-treated DCs (Fig. 5a). Therefore, the
number of NKT cells certainly increased in the live BCG-
activated population. Moreover, those live BCG-activated
NKT cells actually produced to secrete cytocidal molecules
like perforin (Fig. 5b) or granzyme B (data not shown).
Also, it should be noted that the live BCG-activated T
cells became eVector/memory state expressing CD45RO
from naïve state expressing CD45RA although the number
of T cells did not altered (data not shown).
Increased NKT cells inhibited T24 cells 
in a CD1d-unrestricted fashion
In general, NKT cells recognize glycolipid antigens
presented by CD1d [23]. To clarify whether the live BCG-
activated NKT cells see T24 tumor antigens in a CD1d-
restricted manner, the expression of CD1d on T24 cells was
investigated. Despite careful and intense examination, nei-
ther mRNA encoding CD1d nor the surface expression of
CD1d was detected in not only untreated T24 cells but also
BCG-treated ones (Fig. 6a, b), indicating that T24 will not
express CD1d molecules even incorporating BCG into their
cellular component.
Therefore, to exclude the possibility of subtle expres-
sion for functional CD1d on T24 cells after the BCG treat-
ment, an established human NKT line (HT-AC2) that
recognizes -galactosyl ceramide (-GalCer) and secretes
IL-4 in a CD1d-restricted manner (Shimizu & Takahashi,
manuscript in preparation) and C1R/CD1d cells express-
ing human CD1d gene, we examined whether NKT cells
can recognize T24 cells in the presence of -GalCer. No
IL-4 was detected in the supernatant of the NKT cell line
co-cultured with -GalCer-pulsed T24 as well as BCG-
treated T24 cells (Fig. 6c). Collectively, NKT cells but
not NK cells induced by the live BCG-activated DCs
seem to predominantly eliminate or suppress T24 tumor
cells in a CD1d-unrestricted, -GalCer independent
fashion.
Possible tumor cell ligands for BCG-activated NKT cell 
recognition
Because NKG2D expression was observed on the NKT
cells or T cells expanded from live BCG-treated
PBMCs (data not shown), blocking eVect of antibodies
for stress-associated tumor cell-speciWc molecules such
as MICA/MICB [2, 10], the counterparts of NKG2D
receptor, on the recognition of T24 cells was examined
based on the recent Wnding [28]. As demonstrated in
Fig. 7a, signiWcant inhibition of the cytotoxicity medi-
ated by activated NKT cells was seen when anti-MICA/
MICB speciWc antibody was added, although isotype-
Fig. 4 EVect of CD161 positive cells depletion on T24 growth. a The
elimination of CD161-positive cells was conWrmed by Xow cytometry.
b The remaining cells after the elimination of CD161-positive cells
(closed triangle) showed a profound reduction of cytotoxicity against
T24 cells compared to live BCG-activated PBMCs (closed circle). The
Wndings suggest that the residual T cells after the elimination of
CD161-positive cells had slightly stronger cytotoxicity than the acti-
vated NK cells in PBMCs (closed square). c PBMCs activated by live
BCG-treated DCs (closed triangle) showed far stronger cytotoxicity
than BCG-untreated PBMCs (closed circle) against NK-sensitive
K562 cells. These results indicate that NK cells have weaker cytotox-































E / T ratio
25 50 100
PBMC+untreated DC


















1252 Cancer Immunol Immunother (2009) 58:1245–1255matched antibody did not show any inhibition for their
cytotoxicity. Moderate inhibition was also seen when
the NKG2D receptors blocked by their speciWc antibody
(Fig. 7a). Similarly, cytotoxicity against T24 cells by
live BCG-treated PBMCs containing mostly activated
NKT cells as well as some T and NK cells was mark-
edly inhibited by anti-MICA/MICB speciWc antibody
(Fig. 7b). Therefore, MICA/MICB molecules on the T24
cells appear to be a possible tumor cell ligands for BCG-
activated innate NKT cell recognition.
Discussion
Intravesical BCG therapy is probably the most eVective
immunotherapy for recurrent superWcial bladder cancer. As
far as we have examined, the anti-tumor eVect does not
appear to be due to direct cytotoxicity of BCG itself. In
fact, it was recently reported that the treatment of the uro-
thelial carcinoma cell line T24 with BCG did not induce
apoptosis, and BCG inhibited camptothecin-mediated
apoptosis [7]. Similarly, treatment of T24 cells with BCG
Fig. 5 SigniWcant increase and 
perforin production in the num-
ber of NKT cells among PBMCs 
activated by live BCG-treated 
DCs. a Flow-cytometric analysis 
showed that the number of both 
CD3+CD56+ cells, and 
CD3+CD161+ NKT cells but not 
CD3¡CD56+ or CD3¡CD161+ 
NK cells apparently increased 
among those PBMCs activated 
by live BCG-treated DCs but not 
by heat-inactivated BCG-treated 
DCs. Therefore, the number of 
NKT cells certainly increased in 
the live BCG-activated popula-
tion. b The live BCG-activated 
NKT cells actually produced to 
secrete cytocidal molecules like 
perforin, while heat-inactivated 
BCG-associated NKT did not123
Cancer Immunol Immunother (2009) 58:1245–1255 1253did not cause any apoptotic changes as examined with a
TUNEL assay [24]. Therefore, BCG itself does not elimi-
nate T24 tumor cells but rather some immune system acti-
vated by BCG may indirectly inhibit the growth of these
cells or eliminate them.
The body has two distinct immune systems to suppress
tumor growth or eliminate tumor cells. One is systemic
acquired immunity with highly speciWc eVectors such as
class I MHC molecule-restricted CD8+ CTLs, class II
MHC molecule-restricted CD4+ T cells, and speciWc anti-
bodies. These eVectors express speciWc receptors originat-
ing from rearranged genes established by periodic
stimulation. The magnitude of speciWc responses will
increase synergistically with the number of stimulations.
Fig. 6 Inhibition of T24 tumor 
growth by the BCG-activated 
NKT cells was mediated in a 
CD1d-unrestricted manner. 
NKT cells are usually recog-
nized as antigens in association 
with CD1d molecules. Thus, a 
both internal mRNA for CD1d 
expression and b external sur-
face expression were examined 
in T24 tumor cells. However, 
CD1d expression could not be 
detected at all even after co-cul-
tured with live BCG. c There-
fore, using an established human 
NKT line (HT-AC2) that recog-
nizes -galactosyl ceramide 
(-GalCer) in a CD1d-restricted 
manner and secretes IL-4 
(Shimizu & Takahashi, 
manuscript in preparation) and 
CD1d-expressing C1R cells 
(C1R/hCD1d), we investigated 
whether NKT cells can 
recognize live BCG-treated 
(T24-BCG) or untretaed T24 
cells in the presence of 
-GalCer. No IL-4 was detected 
in the supernatant of NKT cells 
co-cultured with -GalCer-
pulsed those T24 cells. Taken 
together, NKT cells generated 
by the live BCG-activated DCs 
seem to inhibit T24 tumor cell 
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tors (TLR),  TCR, or invariant NKT–TCR having
diverse cross-reactivity without requiring the strict gene-
rearrangement seen in the establishment of acquired
immune receptors and their activation can be maintained
by constant stimulation.
Also, as has been indicated, the bladder cancer cell line
T24 expresses markedly down-modulated MHC class I
molecules on its surface and the expression did not
recover by the treatment with live BCG or live BCG-
infected DCs. Thus, the T24 tumor would be recognized
in a MHC molecule-unrestricted manner. Hence, we co-
cultured the T24 cells with allogeneic PBMCs in the pres-
ence of live BCG and found a profound inhibition of
tumor growth in vitro. A similar strong inhibition of T24
cell proliferation was observed when live BCG-infected
DCs were co-cultured with PBMCs of the same donor.
Moreover, the elimination of T24 cells was achieved
mostly by CD3-positive innate eVectors such as V2V2
TCR-expressing T cells and NKT cells having predomi-
nant cytotoxicity, but not by class I MHC molecule-
restricted conventional CD8-positive CTLs, and the
innate eVectors were activated by live BCG-infected DCs
rather than heat-inactivated BCG-treated DCs. Further-
more, the number of NKT cells but not T cells or NK
cells certainly increased in the live BCG-activated popu-
lation.
These results strongly suggest that cells that control
T24 tumor growth are not conventional class I MHC
molecule-restricted CD8+ CTL in the acquired arm but
rather MHC molecule-unrestricted T and NKT cells in
the innate arm through the activation of DCs by live
BCG. The results are reasonable in that continuous stim-
ulation in the limited conWned mucosal compartment of
the bladder by a live organism may activate local innate
eVectors. Although the possible involvement of acquired
eVectors like CD8+ CTLs in the prevention of surface
bladder tumor expansion by intravesical BCG therapy
has not be excluded, the data obtained in the present
study strongly indicate a dominant eVect of innate cells
on tumor recurrence at the conWned mucosal surface.
Moreover, the cytotoxic eVect of innate NKT or T
cells on T24 tumor cells was mediated thought stress-
associated tumor-speciWc MICA/MICB molecules via
their NKG2D receptors but not CD1d molecule-
restricted invariant NKT-TCRs, indicating that these
invariant TCRs are required mainly for their activation.
If this is the actual reason why intravesical BCG therapy
is most successful immunotherapy against solid tumors in
terms of preventing recurrence, we must focus on the con-
stant activation of innate immunity for the treatment of
other solid tumors and preventing their spread by metasta-
sis. The Wndings shown in the present study will open the
new notion that constant stimulation of innate eVectors
such as MHC molecule-unrestricted T and NKT cells
with live microorganisms like BCG through the activation
of local DCs may provide a novel therapeutic way for can-
cer treatment.
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Fig. 7 Possible tumor cell ligands for BCG-activated NKT cell recog-
nition. a EVect of antibodies for blocking stress-associated tumor cell-
speciWc molecules such as MICA/MICB, the counterparts of NKG2D
receptor, on the recognition of T24 cells was examined. SigniWcant
inhibition of the cytotoxicity mediated by activated NKT cells was
seen when anti-MICA/MICB speciWc antibody was added, although
isotype-matched antibody did not show any inhibition for their cyto-
toxicity. Moderate inhibition was also seen when the NKG2D recep-
tors blocked by their speciWc antibody. b Cytotoxicity against T24 cells
by live BCG-treated PBMCs containing mostly activated NKT cells as
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